{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:08Z","timestamp":1649030408523},"reference-count":28,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"DOI":"10.1007\/s10165-012-0828-1","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T11:27:59Z","timestamp":1359372479000},"source":"Crossref","is-referenced-by-count":1,"title":["Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center"],"prefix":"10.1093","author":[{"given":"Yuichiro","family":"Shirai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,1,29]]},"reference":[{"key":"828_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.hfc.2012.04.001","volume":"8","author":"SC Mathai","year":"2012","unstructured":"Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8:413\u201325.","journal-title":"Heart Fail Clin"},{"key":"828_CR2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","volume":"138","author":"L Chung","year":"2010","unstructured":"Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383\u201394.","journal-title":"Chest"},{"key":"828_CR3","doi-asserted-by":"crossref","unstructured":"Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. Rheumatology (Oxford).2012; 51:1846\u201354","DOI":"10.1093\/rheumatology\/kes140"},{"key":"828_CR4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","volume":"60","author":"SC Mathai","year":"2009","unstructured":"Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60:569\u201377.","journal-title":"Arthritis Rheum"},{"key":"828_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","volume":"48","author":"E Hachulla","year":"2009","unstructured":"Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study. Rheumatology. 2009;48:304\u20138.","journal-title":"Rheumatology"},{"key":"828_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R. Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"828_CR7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/03009742.2010.508751","volume":"40","author":"R Hesselstrand","year":"2011","unstructured":"Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol. 2011;40:127\u201332.","journal-title":"Scand J Rheumatol"},{"key":"828_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1378\/chest.10-2327","volume":"140","author":"R Zhang","year":"2011","unstructured":"Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest. 2011;140:301\u20139.","journal-title":"Chest"},{"key":"828_CR9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"828_CR10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425\u201334.","journal-title":"Ann Intern Med"},{"key":"828_CR11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","volume":"13","author":"M Humbert","year":"1999","unstructured":"Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999;13:1351\u20136.","journal-title":"Eur Respir J"},{"key":"828_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","volume":"117","author":"IM Robbins","year":"2000","unstructured":"Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117:14\u20138.","journal-title":"Chest"},{"key":"828_CR13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477\u201382.","journal-title":"Circulation"},{"key":"828_CR14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herv\u00e9 P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"828_CR15","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"RJ Barst","year":"2009","unstructured":"Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S78\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"828_CR16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","volume":"167","author":"KP Kuhn","year":"2003","unstructured":"Kuhn KP, Byrne DW, Arboqast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Resipr Crit Care Med. 2003;167:580\u20136.","journal-title":"Am J Resipr Crit Care Med"},{"key":"828_CR17","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","volume":"36","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36:2244\u20139.","journal-title":"J Rheumatol"},{"key":"828_CR18","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"828_CR19","doi-asserted-by":"crossref","unstructured":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u2013590.","DOI":"10.1002\/art.1780230510"},{"key":"828_CR20","first-page":"23","volume-title":"Mixed connective tissue disease and anti-nuclear antibodies","author":"R Kasukawa","year":"1987","unstructured":"Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Elsevier: Amsterdam; 1987. p. 23\u201332."},{"key":"828_CR21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"828_CR22","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","volume":"30","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;30:S55\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"828_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","volume":"37","author":"M Kuwana","year":"1994","unstructured":"Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37:75\u201383.","journal-title":"Arthritis Rheum"},{"key":"828_CR24","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X","volume":"42","author":"E Klings","year":"1999","unstructured":"Klings E, Hill N, Ieong M, Simms R, Korn J, Farber H. Systemic sclerosis-associated pulmonary hypertension. Arthritis Rheum. 1999;42:2638\u201345.","journal-title":"Arthritis Rheum"},{"key":"828_CR25","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1253\/circj.CJ-10-0190","volume":"74","author":"S Akagi","year":"2010","unstructured":"Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010;74:2200\u20135.","journal-title":"Circ J"},{"key":"828_CR26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.rmed.2011.12.018","volume":"106","author":"SR Johnson","year":"2012","unstructured":"Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respir Med. 2012;106:730\u20139.","journal-title":"Respir Med."},{"key":"828_CR27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","volume":"360","author":"HA Ghofrani","year":"2002","unstructured":"Ghofrani HA, Wiedemann R, Rose F, Schemuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895\u2013900.","journal-title":"Lancet"},{"key":"828_CR28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1378\/chest.118.4.1077","volume":"118","author":"C Strange","year":"2000","unstructured":"Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000;118:1077\u201382.","journal-title":"Chest"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10165-012-0828-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:26:10Z","timestamp":1646843170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-012-0828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,29]]},"references-count":28,"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1007\/s10165-012-0828-1","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,29]]}}}